Nerve Block for Postoperative Pain After ACL Surgery
Trial Summary
What is the purpose of this trial?
Health care providers are seeking methods to limit post-operative pain and opioid prescriptions to reduce the burden of the national opioid use epidemic. Adductor canal block (ACB) is a peripheral nerve block that has been shown to reduce pain and opioid usage with minimal effect on quadriceps function in patients undergoing arthroscopic knee surgery. Infiltration between Popliteal Artery and Capsule of the Knee (iPACK) block has also shown promise in reducing pain and opioid usage, specifically reducing posterior knee pain, which ACB is not able to achieve. To our knowledge, there is currently no study in the orthopedic literature comparing post-operative pain and opioid consumption in ACL reconstruction (ACLR) patients who received isolated ACB versus ACB with IPACK. The primary aim of this study is to investigate the role of IPACK in combination with ACB in reducing peri-operative (14-days) pain levels in ACLR patients. The secondary aim is to determine the effectiveness of IPACK in reducing post-operative opioid use. The tertiary aim is to determine any effect of IPACK on post-operative functional outcomes.
Research Team
Eligibility Criteria
This trial is for patients undergoing their first ACL reconstruction due to a tear, including those with additional meniscus surgery. It's not for people under 18, those having revision surgery, on worker's compensation, or pregnant women.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Adductor Canal Block (ACB) (Local Anesthetic)
- Infiltration between Popliteal Artery and Capsule of the knee (iPACK) (Local Anesthetic)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rothman Institute Orthopaedics
Lead Sponsor